Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6652)
All Articles published online
|
Publishing Process of This Article
|
Sep 6, 2020 (publication date) through Jan 9, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World J Clin Cases 2020; 8(17): 3718-3729 [PMID: 32953848 DOI: 10.12998/wjcc.v8.i17.3718] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i17/3718.htm |
| Number | Citing Articles |
| 1 |
Devon J. Boyne, Darren R. Brenner, Alind Gupta, Eric Mackay, Paul Arora, Radek Wasiak, Winson Y Cheung, Miguel A. Hernán. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology 2023; 78: 28 doi: 10.1016/j.annepidem.2022.12.005
|
| 2 |
Chan Su Park, Byung Kyu Park, Joung-Ho Han, Kyong Joo Lee, Kang Ju Son. Real-World Outcomes of First-Line Chemotherapy in Metastatic Pancreatic Cancer: A Nationwide Population-Based Study in Korea. Cancers 2024; 16(18): 3173 doi: 10.3390/cancers16183173
|
| 3 |
Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Biomolecules 2021; 11(6): 780 doi: 10.3390/biom11060780
|
| 4 |
Kwangrok Jung, Suhyun Choi, Hyunjoo Song, Kyuhan Kwak, Soyeon Anh, Jae Hyup Jung, Bomi Kim, Jinwoo Ahn, Jaihwan Kim, Jin-Hyeok Hwang, Jong-chan Lee. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231175441
|